Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Indoleamine 2,3-dioxygenase vaccination.

Literature DB >> 25949864

Indoleamine 2,3-dioxygenase vaccination.

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.

Entities: Disease Gene Species

Keywords: CD8; DC, dendritic cells; IDO; IDO, indoleamine 2,3-dioxygenase; NSCLC; NSCLC, non-small-cell lung cancer; OS, overall survival; PBMC, peripheral blood mononuclear cells; PD, progressive disease; PD-L1; SD, stable disease; Tregs, regulatory T cells; cancer vaccine

Year: 2015 PMID： 25949864 PMCID： PMC4368142 DOI： 10.4161/2162402X.2014.983770

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

1. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Authors: Rikke Baek Sørensen; Sine Reker Hadrup; Inge Marie Svane; Mads Christian Hjortsø; Per Thor Straten; Mads Hald Andersen
Journal: Blood Date: 2010-11-15 Impact factor: 22.113

2. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.

Authors: S M Ahmad; S K Larsen; I M Svane; M H Andersen
Journal: Leukemia Date: 2013-09-12 Impact factor: 11.528

3. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.

Authors: Rita Fishelevich; Yuming Zhao; Papapit Tuchinda; Hannah Liu; Ayako Nakazono; Antonella Tammaro; Tzu-Ching Meng; Jim Lee; Anthony A Gaspari
Journal: J Immunol Date: 2011-07-15 Impact factor: 5.422

4. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.

Authors: Amy J Davidoff; Mei Tang; Brian Seal; Martin J Edelman
Journal: J Clin Oncol Date: 2010-03-29 Impact factor: 44.544

5. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.

Authors: Rebecca C Harris; Kimberly A Chianese-Bullock; Gina R Petroni; Jochen T Schaefer; Louis B Brill; Kerrington R Molhoek; Donna H Deacon; James W Patterson; Craig L Slingluff
Journal: J Immunother Date: 2012-01 Impact factor: 4.456

Review 6. Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Authors: Alexander J Muller; George C Prendergast
Journal: Curr Cancer Drug Targets Date: 2007-02 Impact factor: 3.428

7. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.

Authors: Trine Zeeberg Iversen; Lotte Engell-Noerregaard; Eva Ellebaek; Rikke Andersen; Stine Kiaer Larsen; Jon Bjoern; Claus Zeyher; Cécile Gouttefangeas; Birthe Moerk Thomsen; Bente Holm; Per Thor Straten; Anders Mellemgaard; Mads Hald Andersen; Inge Marie Svane
Journal: Clin Cancer Res Date: 2013-11-11 Impact factor: 12.531

8. Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan.

Authors: Yoshika Nagata; Takeshi Hanagiri; Makiko Mizukami; Koji Kuroda; Yoshiki Shigematsu; Tetsuro Baba; Yoshinobu Ichiki; Manabu Yasuda; Tomoko So; Mitsuhiro Takenoyama; Kenji Sugio; Akira Nagashima; Kosei Yasumoto
Journal: Lung Cancer Date: 2008-12-02 Impact factor: 5.705

9. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors: Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal: Nat Med Date: 2003-09-21 Impact factor: 53.440

10. FOXP3-specific immunity.

Authors: Mads Hald Andersen
Journal: Oncoimmunology Date: 2013-09-12 Impact factor: 8.110

10 in total

7 in total

Review 1. Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors: Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2016-07-25 Impact factor: 8.110

2. Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy.

Authors: Kei Ishibashi; Takumi Kumai; Takayuki Ohkuri; Akemi Kosaka; Toshihiro Nagato; Yui Hirata; Kenzo Ohara; Kensuke Oikawa; Naoko Aoki; Naoko Akiyama; Masatoshi Sado; Masahiro Kitada; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal: Oncoimmunology Date: 2016-03-30 Impact factor: 8.110